CORT News & Events

Reports Q4 revenue $202.1M, consensus $254.94M. "In 2025, our Cushing's syndrome business experienced a surge in demand due to growing recognition among physicians of hypercortisolism's true prevalence and the necessity of appropriate treatment. We had a record number of new prescriptions written for our medications and a record number of new prescribers in 2025, which translated to a 37 percent increase in the number of tablets sold compared to the prior year. We should have achieved higher growth but were not able to fully meet demand because of capacity constraints at our previous specialty pharmacy vendor. There were also operational disruptions in the fourth quarter as we transitioned our business to our new specialty pharmacy. This transition is now fully complete and February is on track to be a record month for the number of new patients that have started treatment with our medications. We expect that our Cushing's syndrome business will expand for many years," said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer.

The major averages closed broadly lower, giving back some of Wednesday's gains as investors responded to the latest slate of quarterly earnings reports and continue to monitor tensions between the U.S. and Iran. Growing concerns also remain about lingering uncertainty over the Federal Reserve's rate path.Looking to commodities, gold was fractionally lower, with the "safe haven" asset still hovering above the $5,000 threshold. Oil rose amid the tensions in Iran.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Walmartreported, provided its outlook for Q1 and FY27, announced a new $30B share buyback program, and raised its quarterly dividendeBayreportedand agreed to acquire Depop from Etsyfor $1.2B in cashMeanwhile, EtsyreportedDeerereportedand provided its outlook for FY26DoorDashreported downbeat2. WALL STREET CALLS:Chewyto Outperform at Raymond JamesDaiwaVerizonto Buy from Outperform and T-Mobileto Outperform from NeutralShopifyto Buy at Phillip SecuritiesCheesecake Factoryto Equal Weight at StephensFiverrto Neutral at JPMorgan and Citi3. AROUND THE WEB:Netflixhas ample cash to boost its Warner Bros. Discoveryoffer, Reuters reportsJohnson & Johnsonis weighing selling its DePuy business amid private equity interest, Bloomberg saysAMDwill effectively guarantee a $300M loan for data center and cloud startup Crusoe to purchase AMD's AI chips and install them in a data center in Ohio, The Information reportsKinetik, a $7.2B gas pipeline operator with roughly 4,600 miles of pipeline in the Delaware Basin, is considering a sale following interest from Western Midstream Partners, backed by Occidental Petroleum, FT saysMetaplans to spend $65M to boost state politicians who are friendly to the AI industry, NY Times says4. MOVERS:Remitlyincreases afterand appointing Sebastian Gunningham as CEOHerbalifegains afterand announcing Cristiano Ronaldo invested $7.5M in Pro2col technologyTalkspaceand Omnicomhigher afterCorcept Therapeuticsfalls after the U.S. Court of Appeals for the Federal Circuitin a patent case with TevaEpam Systemand N-ablelower after5. EARNINGS/GUIDANCE:Integer, with CEO Payman Khales commenting, "Integer delivered strong performance in 2025"Travelzooand providing guidance for Q1Klarna, with revenue beating consensusUpbound Groupand providing guidance for Q1 and FY26LKQ Corp., with CEO Justin Jude commenting "Throughout 2025, our team relentlessly focused on what we could control, resulting in significant free cash flow generation despite sector headwinds across our global enterprise"INDEXES:The Dow fell 267.50, or 0.54%, to 49,395.16, the Nasdaq lost 70.91, or 0.31%, to 22,682.73, and the S&P 500 declined 19.42, or 0.28%, to 6,861.89.